<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754728</url>
  </required_header>
  <id_info>
    <org_study_id>LBCT-H01-07</org_study_id>
    <nct_id>NCT00754728</nct_id>
  </id_info>
  <brief_title>&quot;JACTAX&quot; Trial Drug Eluting Stent Trial</brief_title>
  <official_title>&quot;JACTAX&quot; Trial Drug Eluting Stent Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Labcoat, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, non-randomized registry. 100 patients will be enrolled at up to 10&#xD;
      clinical sites in Europe. The results of this study will be compared to the TAXUS™ ATLAS&#xD;
      clinical trial to evaluate the safety of the product.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The JACTAX Drug Eluting Stent has been designed to minimize the amount of polymer in contact&#xD;
      with the vessel surface, thus potentially reducing the incidence of untoward side effects.&#xD;
      The Juxtaposed Ablumenal Coating Process is capable of exclusive coating on the ablumenal&#xD;
      side of pre-mounted bare metal stents. Juxtaposed Ablumenal Coating is a proprietary&#xD;
      formulation containing a bioerodable polymer. The combination of the Juxtaposed Ablumenal&#xD;
      Coating Process and Juxtaposed Ablumenal Coating create a unique microstructure surface, and&#xD;
      reduces the amount of required polymer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE at 9 months</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JACTAX DES</intervention_name>
    <description>Drug Eluting Stent</description>
    <arm_group_label>I</arm_group_label>
    <other_name>JACTAX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          1. Patient is ≥ 18 years of age&#xD;
&#xD;
          2. Patient is eligible for percutaneous coronary intervention (PCI)&#xD;
&#xD;
          3. Patient demonstrates LVEF of ≥ 25%&#xD;
&#xD;
          4. Patient or legal guardian understands and agrees to comply with all specified study&#xD;
             requirements and provides written informed consent to this effect&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Target lesion is de novo native coronary artery lesion (i.e., a coronary lesion not&#xD;
             previously treated)&#xD;
&#xD;
          2. Target lesion can be treated with one stent, with overlap onto the healthy tissue, as&#xD;
             specified in visual estimate guidelines.Max lesion length is 20 mm(i.e. approximately&#xD;
             4mm on each side, based on visual estimate and available stent lengths)&#xD;
&#xD;
          3. Reference vessel diameter is between 2.75mm and 3.5 mm&#xD;
&#xD;
          4. Study lesion diameter stenosis is ≥70%&#xD;
&#xD;
          5. Study lesion has been successfully pre-dilated&#xD;
&#xD;
          6. Patients enrolled for treatment may demonstrate multiple lesions in target vessel.&#xD;
             However lesions must be covered completely by one study stent&#xD;
&#xD;
          7. Patient must have no more than two lesions requiring treatment. These lesions must be&#xD;
             in different vessel distributions. For example, if the target lesion is in the LAD,&#xD;
             then the non target lesion must be present in either the circumflex or RCA. The&#xD;
             non-study lesion may not be in a branch vessel or distal to the target vessel location&#xD;
&#xD;
          8. The non target lesion must be successfully treated prior to the treatment of the&#xD;
             target lesion. The non target lesion must be treated with either a TAXUS paclitaxel&#xD;
             eluting stent or a bare metal stent.&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. The patient has a life expectancy of less than 24 months due to another medical&#xD;
             condition&#xD;
&#xD;
          2. Patient has a history of hypersensitivity to paclitaxel or structurally related&#xD;
             compounds&#xD;
&#xD;
          3. Patient exhibits cardiogenic shock (systolic pressure &lt;80 mmHg and PCWP&gt; 20mm Hg or&#xD;
             cardiac index &lt;1.8 liters/m or intra-aortic balloon pump or intravenous inotropes are&#xD;
             needed to maintain a systolic pressure &gt;80 mmHg) for any time within 24 hours prior to&#xD;
             index procedure&#xD;
&#xD;
          4. Patient demonstrates evidence of acute or chronic renal dysfunction (serum creatinine&#xD;
             &gt;2.0 mg/dl or 177umol/l)&#xD;
&#xD;
          5. Planned cardiac surgery procedure &lt;= 9 months post index procedure&#xD;
&#xD;
          6. Patient demonstrates evidence of a myocardial infarction (elevated CK, CKMB or&#xD;
             Troponin) within 72 hours prior to index procedure and/or CK&gt; 2X local lab's ULN,&#xD;
             unless CK-MB is &lt;2X ULN&#xD;
&#xD;
          7. Patient exhibits acute ST segment elevation MI (STEMI) within 72 hours prior to the&#xD;
             index procedure&#xD;
&#xD;
          8. CVA including stroke or TIA within 3 months&#xD;
&#xD;
          9. Patient demonstrates evidence of leukopenia&#xD;
&#xD;
         10. Patient demonstrates evidence of thrombocytopenia or thrombocytosis&#xD;
&#xD;
         11. Patient is contraindicated to ASA, clopidogrel or ticlopidine&#xD;
&#xD;
         12. Patient is currently on warfarin, or possibility of treatment with warfarin during the&#xD;
             following 6 months post index procedure&#xD;
&#xD;
         13. Patient has been treated with paclitaxel or other chemotherapeutic agents within 12&#xD;
             months prior to planned index procedure&#xD;
&#xD;
         14. Anticipated treatment with paclitaxel or oral rapamycin during any period in the 9&#xD;
             months after the index procedure&#xD;
&#xD;
         15. Patient has received a drug eluting stent within 12 months prior to planned index&#xD;
             procedure&#xD;
&#xD;
         16. Previous or planned treatment with intravascular brachytherapy in target vessel&#xD;
&#xD;
         17. Known allergy to stainless steel&#xD;
&#xD;
         18. Male or female with known intention to procreate within 3 months after the index&#xD;
             procedure&#xD;
&#xD;
         19. Female of childbearing potential with a positive pregnancy test within 7 days before&#xD;
             the index procedure, or lactating or intends to become pregnant during the 12 months&#xD;
             post index procedure&#xD;
&#xD;
        Angiographic Exclusion Criteria&#xD;
&#xD;
          1. Evidence of probable or definite thrombus of the study vessel, based on angiography or&#xD;
             IVUS&#xD;
&#xD;
          2. Study lesion is totally occluded (TIMI flow &lt;= 1) either at baseline or before&#xD;
             pre-dilatation&#xD;
&#xD;
          3. Study lesion, or the study vessel proximal to the study lesion is moderately or&#xD;
             severely calcified by visual estimate&#xD;
&#xD;
          4. Study lesion is ostial in location (within 3.0 mm of vessel origin)&#xD;
&#xD;
          5. Study lesion involving arterial segments with highly tortuous anatomy or where lesion&#xD;
             is located within or distal to a &gt;60 degree bend in the vessel&#xD;
&#xD;
          6. Study lesion involves a bifurcation with a diseased (&gt;50% stenotic) branch vessel &gt;2.0&#xD;
             mm in diameter&#xD;
&#xD;
          7. Left main coronary artery disease (stenosis &gt;50%) branch vessel &gt; 2.0 mm in diameter&#xD;
&#xD;
          8. Target lesion length &gt;20 mm based on visual estimate by operator&#xD;
&#xD;
          9. Target vessel diameter &gt;3.5 mm based on visual estimate by operator&#xD;
&#xD;
         10. Target vessel diameter &lt;2.75 mm based on visual estimate by operator&#xD;
&#xD;
         11. Pre-treatment of the target lesion (excluding predilation) with another interventional&#xD;
             device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eberhard Grube</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elizabeth Hospital, Essen Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburg University CardioVascular Center</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum</name>
      <address>
        <city>Siegburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankehaus der Barmherzigen Bruder</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton NHS</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

